Cargando…
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
BACKGROUND: The phase IIIb CompLEEment-1 study evaluated ribociclib plus letrozole in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). Outcomes were investigated in the following subgroups: central nervous system (...
Autores principales: | Cottu, Paul, Ring, Alistair, Abdel-Razeq, Hikmat, Marchetti, Paolo, Cardoso, Fatima, Salvador Bofill, Javier, Martín, Miguel, Menon-Singh, Lakshmi, Wu, Jiwen, De Laurentiis, Michelino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073296/ https://www.ncbi.nlm.nih.gov/pubmed/35131646 http://dx.doi.org/10.1016/j.breast.2022.01.016 |
Ejemplares similares
-
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
por: De Laurentiis, Michelino, et al.
Publicado: (2021) -
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
por: De Laurentiis, Michelino, et al.
Publicado: (2021) -
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study
por: De Laurentiis, Michelino, et al.
Publicado: (2022) -
Ribociclib Plus Letrozole in Patients with Hormone Receptor-positive, HER2-negative Advanced Breast Cancer with No Prior Endocrine Therapy: Subgroup Safety Analysis from The Phase 3b CompLEEment-1 Trial
por: Borstnar, Simona, et al.
Publicado: (2022) -
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
por: Salvador Bofill, Javier, et al.
Publicado: (2022)